Intravenous fosfomycin treatment for carbapenem-resistant klebsiella pneumoniae in the United States

Annals of Pharmacotherapy

Volumn 49, Issue 10, 2015, Pages 1177-1178

  Simkins, Jacques ^a   Fan, Ji ^a   Camargo, Jose F ^a   Aragon, Laura ^b   Frederick, Corey ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; COLISTIN; FOSFOMYCIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POTASSIUM; RIFAMPICIN; TIGECYCLINE; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; CANDIDIASIS; CASE REPORT; FEMALE; GRAFT FAILURE; HUMAN; INTENSIVE CARE; INTESTINE ISCHEMIA; KLEBSIELLA PNEUMONIAE INFECTION; LENGTH OF STAY; LETTER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MIDDLE AGED; MULTIPLE ORGAN FAILURE; NONALCOHOLIC FATTY LIVER; POSTOPERATIVE PERIOD; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RECURRENT INFECTION; SEPTIC SHOCK; UNITED STATES; BACTEREMIA; FATALITY; INTRAVENOUS DRUG ADMINISTRATION; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIOLOGY;

ADMINISTRATION, INTRAVENOUS; ANTI-BACTERIAL AGENTS; BACTEREMIA; FATAL OUTCOME; FOSFOMYCIN; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LIVER TRANSPLANTATION; MIDDLE AGED; UNITED STATES;

EID: 84952772949     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028015598326     Document Type: Letter

References (6)

1. Kyle JM, Stollings JL, White KD, Noto MJ, Wheeler AP. Fosfomycin for multidrug treatment of Klebsiella pneumoniae carbapenemase bacteremia. Ann Pharmacother. 2015;49:366-367.
2. Varghese JM, Roberts JA, Lipman J. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin. 2011;27:19-34.
3. Navarro-San Francisco C, Mora-Rillo M, Romero-Gómez MP, et al. Bacteraemia due to OXA-48-carbapenemaseproducing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect. 2013;19:E72-E79.
4. Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drugresistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents. 2014;43:52-59.
5. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenemresistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect. 2010;16: 184-186.
6. Karageorgopoulos DE, Miriagou V, Tzouvelekis LS, Spyridopoulou K, Daikos GL. Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. J Antimicrob Chemother. 2012;67:2777-2779.